News | October 12, 2009

Minneapolis Heart Institute Hosts Cardiac Therapeutic Hypothermia Conference

October 13, 2009 – The Minneapolis Heart Institute at Abbott Northwestern Hospital with guest national faculty will present The Miracle on Ice: Therapeutic Hypothermia for Cardiac Arrest Patient Dec. 3-4, a conference that will draw physicians from across the country to learn how innovative rescue and cooling programs are saving lives and preserving brain function in cardiac arrest victims.

“The Minneapolis Heart Institute’s ‘Cool It’ therapeutic hypothermia program has become the national model for emergency cardiac resuscitation,” said Kevin J. Graham, M.D., cardiologist and president of the Minneapolis Heart Institute at Abbott Northwestern Hospital. “With our partners around the state, we were the first in the world to offer therapeutic hypothermia systematically to patients throughout a region who are then transferred post arrest to a quaternary referral center. Our survival and recovery numbers are even more impressive because the majority of the patients in this program are transferred to us after initial stabilization at a regional hospital.”

Karl Kern, M.D., of the University of Arizona, a national expert in emergency cardiac resuscitation and a conference speaker, says progress has been made in survival from out-of-hospital cardiac arrest with improved CPR techniques, but better survival rates are possible. “The next great opportunity for improving outcomes from cardiac arrest will be through more aggressive and appropriate post-resuscitation care,” he said. “Optimal post-resuscitation care includes the routine use of mild hypothermia combined with early coronary angiography and possible angioplasty. Where such is currently being practiced, survival rates of 70 percent have been reported, with 80 percent of such survivors being neurologically intact.”

Dr. Graham says more than 100 programs across the nation have visited Minneapolis to learn about the MHI Level One MI program.

The Miracle on Ice conference will be held from 7 a.m. to 5 p.m. Thursday and Friday, Dec. 3-4, at the Marriott Minneapolis Airport, 2020 American Boulevard East, Bloomington, Minn.

For more information:

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Overlay Init